L7 Informatics provides a comprehensive operating environment and software stack that brings flexible, secure, and collaborative data+intelligence to life sciences and healthcare organizations. Its L7|ESP platform functions as an end-to-end transformation engine that optimizes the flow of information between processes and people across clinical, research, and manufacturing value chains. The company positions its stack to unlock innovation at every stage of those value chains and to solve contemporary data-intelligence challenges. Management announced a $38 million investment to support the business. The new funding is intended to accelerate product development, expand L7|ESP's global reach, and strengthen customer support. L7 is headquartered in Austin, TX. L7 Informatics provides the Enterprise Science Platform (L7|ESP), a software platform that simplifies data management and digitalizes and automates workflows for therapeutics, diagnostics, medicine, research, and agrochemical industries. The platform aims to enable efficiencies, compliance, reduced costs, and improved operational velocity for enterprise science operations. The company serves life sciences and healthcare customers with solutions for enterprise-scale digital transformation and scientific process automation. Led by CEO Dr. Vasu Rangadass, L7 focuses on commercializing its platform to drive broader adoption. The company announced a Series B financing to support those commercialization efforts. L7 is based in Austin, Texas. Lab7 Systems builds the Enterprise Science Platform (ESP) to help life science laboratories manage complex sample-to-answer workflows in data-intensive environments. The company also curates BioBuilds, a distribution hub for Open Source bioinformatics tools. Lab7 aims to integrate next-generation, computationally intense tools into research practice while preserving data provenance and supporting regulatory compliance. The company positions its software to reduce hands-on data management burden on bioinformaticians, scientists, and IT teams. Lab7 plans to use new financing to enhance its core software platform and expand its team of software developers and bioinformaticians. It is pursuing broader commercial presence to accelerate life-science innovation across fields from precision medicine to industrial biotechnology.

Total raised

$54M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2022